MedTrace Logo

Phase 1 Pharmacokinetics, Safety, and Tolerability Study

NCT04067947 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-02-20

No results posted yet for this study

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose Study of the Pharmacokinetics, Safety, and Tolerability of XG005 in Healthy Volunteers.

Conditions

Interventions

DRUG

XG005

XG005 Tablet

DRUG

Placebos

Placebo Tablet

Sponsors & Collaborators

  • Xgene Pharmaceutical Group

    lead INDUSTRY

Principal Investigators

  • Feng Xu, PHD · Xgene Pharmaceutical Group

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2019-12-03
Completion
2020-02-10

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04067947 on ClinicalTrials.gov